文献速递浆细胞疾病

达雷妥尤单抗联合来那度胺用于新诊断多发性骨髓瘤移植后维持治疗:AURIGA研究

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.
PubMed 文献 · Blood · 2025-01-01

3期AURIGA研究将200例移植后微小残留病(MRD)阳性(10⁻⁵)且抗CD38初治的新诊断多发性骨髓瘤患者随机分配至达雷妥尤单抗联合来那度胺(D-R)维持组(n=99)或来那度胺(R)单药维持组(n=101),维持治疗最多36个周期;D-R组12个月内MRD阴性(10⁻⁵)转换率显著高于R组(50.5% vs 18.8%;OR 4.51;95%CI 2.37-8.57;P<.0001),中位随访32.3个月时无进展生存期(PFS)也优于R组(HR 0.53;95%CI 0.29-0.97),未发现新的安全性问题。

要点

  • D-R维持组12个月内MRD阴性(10⁻⁵)转换率为50.5%,显著高于R组的18.8%(OR 4.51;95%CI 2.37-8.57;P<.0001)。
  • 中位随访32.3个月,D-R组PFS优于R组(HR 0.53;95%CI 0.29-0.97),30个月PFS率分别为82.7%和66.4%。
  • D-R组3/4级血细胞减少发生率为54.2%(R组46.9%),感染为18.8%(R组13.3%),未发现新的安全性问题。

核心结论

  • 移植后D-R维持治疗相比R单药维持,获得了更高的MRD阴性转换率和更优的PFS,且未发现新的安全性问题。

研究设计与样本

  • 3期AURIGA研究纳入移植后达到非常好的部分缓解及以上、MRD阳性(10⁻⁵)且抗CD38初治的新诊断多发性骨髓瘤患者200例,按1:1随机分配至D-R组(n=99)或R组(n=101),维持治疗最多36个周期。

主要发现

  • 自维持治疗开始12个月内MRD阴性(10⁻⁵)转换率:D-R组50.5% vs R组18.8%(OR 4.51;95%CI 2.37-8.57;P<.0001)。
  • MRD阴性(10⁻⁶)转换率:D-R组23.2% vs R组5.0%(OR 5.97;95%CI 2.15-16.58;P=.0002)。
  • 中位随访32.3个月,总体MRD阴性(10⁻⁵)转换率:D-R组60.6% vs R组27.7%(OR 4.12;95%CI 2.26-7.52;P<.0001)。
  • 中位随访32.3个月,完全缓解及以上比例:D-R组75.8% vs R组61.4%(OR 2.00;95%CI 1.08-3.69;P=.0255)。
  • PFS:D-R组对比R组的HR为0.53(95%CI 0.29-0.97);30个月PFS率估计值D-R组82.7% vs R组66.4%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

No randomized trial has directly compared daratumumab and lenalidomide (D-R) maintenance with standard-of-care lenalidomide (R) alone after transplant. Herein, we report the primary results of the phase 3 AURIGA study evaluating D-R vs R maintenance in patients with newly diagnosed multiple myeloma (NDMM) who had very good or better partial response, were minimal residual disease (MRD)-positive (10-5) and anti-CD38-naïve after transplant. Two hundred patients were randomly assigned (1:1) to D-R (n = 99) or R (n = 101) maintenance for up to 36 cycles. The MRD-negative (10-5) conversion rate by 12 months from start of maintenance (primary end point) was significantly higher for D-R than R (50.5% vs 18.8%; odds ratio [OR], 4.51; 95% confidence interval [CI], 2.37-8.57; P < .0001). MRD-negative (10-6) conversion rate was similarly higher with D-R (23.2% vs 5.0%; OR, 5.97; 95% CI, 2.15-16.58; P = .0002). At median follow-up (32.3 months), D-R achieved a higher overall MRD-negative (10-5) conversion rate (D-R, 60.6% vs R, 27.7%; OR, 4.12; 95% CI, 2.26-7.52; P < .0001) and complete response rate or better (75.8% vs 61.4%; OR, 2.00; 95% CI, 1.08-3.69; P = .0255) vs R. Progression-free survival (PFS) favored D-R vs R (hazard ratio, 0.53; 95% CI, 0.29-0.97); estimated 30-month PFS rates were 82.7% for D-R and 66.4% for R. Incidences of grade 3/4 cytopenias (54.2% vs 46.9%) and infections (18.8% vs 13.3%) were slightly higher with D-R than R. In conclusion, D-R maintenance achieved a higher MRD-negative conversion rate and improved PFS after transplant vs R, with no new safety concerns. This trial was registered at www.clinicaltrials.gov as #NCT03901963.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Badros A, Foster L, Anderson LD, et al. Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study. Blood. 2025. PMID: 39331724. doi:10.1182/blood.2024025746

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。